Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Olaratumab.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Olaratumab.
Anthrax immune globulin, human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Olaratumab.
Advertisement
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Olaratumab.
BCG, Live, Connaught Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Olaratumab.
BCG, Live, Tice Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Olaratumab.
Advertisement
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Olaratumab.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Olaratumab.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Olaratumab.
Advertisement
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Olaratumab.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Olaratumab.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Olaratumab.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Olaratumab.
Digoxin
Digoxin may decrease the cardiotoxic activities of Olaratumab.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Olaratumab.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Olaratumab.
Hepatitis A Vaccine, Inactivated
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Olaratumab.
Hepatitis B Surface Antigen Vaccine
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Olaratumab.
Ouabain
Ouabain may decrease the cardiotoxic activities of Olaratumab.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Olaratumab.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Olaratumab.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Olaratumab.
Rabies Immune Globulin, Human
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Olaratumab.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Olaratumab.
ROTAVIRUS VACCINE, LIVE
The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Olaratumab.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Olaratumab.
Salmonella enterica subsp. enterica serovar typhi
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Olaratumab.
Tetanus Toxoid Vaccine, Inactivated
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Olaratumab.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Olaratumab.
Typhoid Vaccine Live Ty21a
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Olaratumab.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Olaratumab.
Varicella Virus Vaccine Live (Oka-Merck) strain
The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Olaratumab.
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Olaratumab.
Yellow-Fever Virus Vaccine, 17D-204 strain
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Olaratumab.
